Glutamine aminotransferase 1000 U/L is an elevated level, which is mostly indicative of impaired liver function and does not confirm the diagnosis of hepatocellular carcinoma. Glutamine aminotransferase is mainly distributed in the myocardium, followed by tissues such as liver, skeletal muscle and kidney. Its serum concentration can be elevated, generally suggesting myocardial infarction, myocarditis, and impaired liver function. Abnormally elevated conditions are mainly: 1. Impaired liver function: common in acute viral hepatitis, cirrhosis, hepatocellular carcinoma, hepatic stasis, biliary obstruction, etc., which may be manifested by elevated levels, but some patients may also be normal. 2. Impaired heart: glutamine aminotransferase has the highest content in cardiomyocytes, serum glutamine aminotransferase activity increases in myocardial infarction; if it decreases and then rises again, it suggests that the infarct foci are enlarged or new infarcts are occurring. 3. Muscle and kidney lesions: myositis, extrusion syndrome, muscle injury, nephritis and so on. Hepatocellular carcinoma is a malignant tumor occurring in the liver, and the diagnosis can be made with the help of serology, imaging and pathology. Serum transaminases are commonly used to assess liver function. Serum alkaline phosphatase, gamma glutamyl transpeptidase, and some isoenzymes of lactate dehydrogenase may be increased in patients with hepatocellular carcinoma, but they lack specificity for the diagnosis of hepatocellular carcinoma and need to be combined with other tests. In conclusion, elevated aminotransferase in patients with hepatocellular carcinoma does not necessarily mean hepatocellular carcinoma. It is recommended to go to regular hospitals for comprehensive assessment of the disease and evaluate the disease through various examinations.